RecruitingPhase 2NCT06561347

Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM

A Phase 2 Multicenter Study of the Combination Zanubrutinib, Bendamustine, and Rituximab in Previously Untreated Waldenström Macroglobulinemia (ZEBRA Trial)

Sponsor

Massachusetts General Hospital

Enrollment

56 participants

Start Date

Dec 20, 2024

Study Type

INTERVENTIONAL

Conditions

Waldenstrom Macroglobulinemia

Summary

The purpose of this study is to determine the very good partial response (VGPR) or better rate in participants with Waldenström macroglobulinemia (WM). The names of the study drugs involved in this study are as follows: zanubrutinib, bendamustine, and rituximab.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Bendamustine, a drug called Rituximab, and others for people with waldenstrom macroglobulinemia. The study is currently recruiting participants at 5 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.